News

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, today announced the closing of the full overallotment option to purchase an additional 562,500 shares at a price of $8.00 per share granted to the underwriters in connection with Tekmira’s previously completed public offering of common stock, increasing the total gross proceeds to US$34.5 million.

Tekmira was represented by Farris LLP, with a team lead by Hector MacKay-Dunn, Q.C. that included Peter Roth and James Campbell.

To view the full press release, please click here.

• Recent News
• News Categories
  • Articles
  • Bulletins
  • News
  • News Releases
• Archived News